We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ACXP

Price
0.35
Stock movement up
+0.02 (5.60%)
Company name
Acurx Pharmaceuticals LLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
5.99M
Ent value
3.54M
Price/Sales
-
Price/Book
2.25
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-80.95%
3 year return
-53.57%
5 year return
-
10 year return
-
Last updated: 2025-04-11

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACXP does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.25
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count16.89M
EPS (TTM)-173.26
FCF per share (TTM)-497.28

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-16.44M
Net income (TTM)-2.84B
EPS (TTM)-173.26
EPS (1y forward)-2.06

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash5.76M
Net receivables97.37K
Total current assets5.98M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets5.98M
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities3.32B
Total liabilities3.32M
Shareholder's equity2.66M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-8.14B
Capital expenditures (TTM)0.00
Free cash flow (TTM)-8.14B
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-106427.09%
Return on Assets-47389.70%
Return on Invested Capital-106427.09%
Cash Return on Invested Capital-214748.36%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.34
Daily high0.36
Daily low0.34
Daily Volume102K
All-time high7.89
1y analyst estimate11.19
Beta-1.72
EPS (TTM)-173.26
Dividend per share-
Ex-div date-
Next earnings date13 May 2025

Downside potential

Loading...
Downside potential data
ACXPS&P500
Current price drop from All-time high-95.51%-12.89%
Highest price drop-96.13%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-60.93%-11.07%
Avg time to new high955 days12 days
Max time to new high954 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACXP (Acurx Pharmaceuticals LLC) company logo
Marketcap
5.99M
Marketcap category
Small-cap
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Employees
4
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...